Illumina jumps 7.1% as Q1 results top expectations and full-year outlook rises

Illumina (ILMN) is up 7.1% today. Here is some analysis on what might have caused this price movement.

Analysis: Illumina’s shares appear to be moving higher after the company reported first-quarter fiscal 2026 results that came in above expectations and lifted its full-year 2026 guidance. The combination of improving profitability and a more optimistic outlook likely drove a reassessment of near-term earnings power.

Details:

Illumina reported Q1 FY2026 results with revenue and non-GAAP EPS coming in ahead of prior expectations, signaling a stronger start to the year than the market had priced in.

The company raised its FY2026 outlook, including higher non-GAAP EPS and revenue targets, which can materially impact valuation models for a stock like ILMN.

Management commentary highlighted momentum factors such as clinical demand and continued NovaSeq X instrument placements, which investors often view as leading indicators for consumables pull-through.

Margins and profitability metrics improved versus prior periods, reinforcing the narrative of operating leverage as revenue growth stabilizes.

Sources:

Illumina Investor Relations, Zacks, The Motley Fool

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$ILMN Insider Trading Activity

$ILMN insiders have traded $ILMN stock on the open market 6 times in the past 6 months. Of those trades, 2 have been purchases and 4 have been sales.

Here’s a breakdown of recent trading of $ILMN stock by insiders over the last 6 months:

PATRICIA LECKMAN (SVP, Chief People Officer) sold 2,370 shares for an estimated $275,346
SCOTT M DAVIES (Chief Legal Officer) has made 0 purchases and 2 sales selling 1,659 shares for an estimated $199,173.
SCOTT GOTTLIEB has made 2 purchases buying 700 shares for an estimated $84,627 and 0 sales.
CHRISTENSEN JAKOB WEDEL (SVP, Strategy/Corp Development) sold 549 shares for an estimated $70,969

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.

EARLY ACCESS

Receive ILMN Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$ILMN Hedge Fund Activity

We have seen 405 institutional investors add shares of $ILMN stock to their portfolio, and 388 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 4,772,083 shares (-75.0%) from their portfolio in Q4 2025, for an estimated $625,906,406
INVESCO LTD. added 1,352,731 shares (+97.0%) to their portfolio in Q4 2025, for an estimated $177,424,197
SESSA CAPITAL IM, L.P. removed 1,282,720 shares (-27.4%) from their portfolio in Q4 2025, for an estimated $168,241,555
POINTSTATE CAPITAL LP removed 1,268,065 shares (-70.4%) from their portfolio in Q4 2025, for an estimated $166,319,405
AQR CAPITAL MANAGEMENT LLC added 1,028,099 shares (+30.3%) to their portfolio in Q4 2025, for an estimated $134,845,464
MORGAN STANLEY added 1,005,474 shares (+66.0%) to their portfolio in Q4 2025, for an estimated $131,877,969
NORDEA INVESTMENT MANAGEMENT AB added 911,843 shares (+2792.2%) to their portfolio in Q4 2025, for an estimated $119,597,327

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.

$ILMN Government Contracts

We have seen $31,546,749 of award payments to $ILMN over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

ILLUMINA REAGENT CHEMISTRY KITS: $1,368,526
ILLUMINA REAGENTS AND CONSUMABLES: $999,049
ILLUMINA DRAGEN GENOMIC ANALYSIS SYSTEM: $663,214
EASTERN LAB, MIDWEST LAB, WESTERN LAB QUARTER FOUR FY25 TASK ORDER FOR WGS KITS UNDER CONTRACT 1232SA25D000...: $625,942
REAGENTS FOR WHOLE GENOME SEQUENCING ON THE ILLUMINA I100 KISEQ AND NEXTSEQ PLATFORM: $564,947

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.

$ILMN Congressional Stock Trading

Members of Congress have traded $ILMN stock 2 times in the past 6 months. Of those trades, 1 have been purchases and 1 have been sales.

Here’s a breakdown of recent trading of $ILMN stock by members of Congress over the last 6 months:

REPRESENTATIVE GILBERT RAY CISNEROS, JR. purchased up to $15,000 on 02/10.
REPRESENTATIVE LISA C. MCCLAIN sold up to $15,000 on 10/31.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API.

$ILMN Analyst Ratings

Wall Street analysts have issued reports on $ILMN in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Stifel issued a "Buy" rating on 01/20/2026

To track analyst ratings and price targets for $ILMN, check out Quiver Quantitative's $ILMN forecast page.

$ILMN Price Targets

Multiple analysts have issued price targets for $ILMN recently. We have seen 8 analysts offer price targets for $ILMN in the last 6 months, with a median target of $152.5.

Here are some recent targets:

Vijay Kumar from Evercore ISI Group set a target price of $155.0 on 05/01/2026
Casey Woodring from JP Morgan set a target price of $125.0 on 05/01/2026
Luke Sergott from Barclays set a target price of $122.0 on 05/01/2026
David Westenberg from Piper Sandler set a target price of $170.0 on 02/09/2026
Kyle Mikson from Canaccord Genuity set a target price of $150.0 on 01/26/2026
Subbu Nambi from Guggenheim set a target price of $170.0 on 01/26/2026
Daniel Arias from Stifel set a target price of $155.0 on 01/20/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.